GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Gain Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$1.25−0.01 (-0.79%)

Close on Oct 19, 2026

Market cap: $53.60M
P/E (TTM): –
Dividend yield: –

Gain Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Depreciation & Amortization	0.03	0.02	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Stock-Based Compensation	0.57	0.40	0.40	0.46	0.52	0.42	0.36	0.36	1.48	0.19	0.56	0.82	1.32	0.57	0.56	0.36	0.31	0.31	0.29	0.25	0.19	0.11	0.08	–	–	–
Other Non-Cash Items	-0.10	-0.23	-0.01	-0.01	-0.67	-0.11	-0.55	0.04	0.17	0.20	0.14	0.17	-0.05	0.12	0.14	0.04	–	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.02	0.33	–	–	-0.01	0.11	–	–
Change in Accounts Payable	-0.49	0.53	-0.79	-0.95	0.15	1.11	-0.06	-1.85	1.48	0.70	-1.03	-0.05	-0.68	1.06	-0.47	0.30	-0.51	1.74	-1.78	1.16	0.01	0.08	0.27	0.16	0.15	-0.18
Operating Cash Flow	-4.68	-4.73	-4.62	-4.93	-5.10	-3.82	-3.45	-6.08	-5.76	-3.59	-5.66	-3.97	-5.02	-4.22	-3.90	-3.29	-5.05	-2.45	-4.15	-2.19	-3.22	-2.81	-1.31	-0.76	-0.42	-0.75
Capital Expenditures	–	–	–	–	–	–	0.00	0.00	–	–	0.00	0.00	0.00	-0.01	-0.01	-0.06	-0.04	-0.01	-0.01	-0.03	-0.02	-0.03	-0.01	0.00	0.00	0.00
Purchase of Investments	–	–	–	–	–	–	–	–	–	–	0	0	0	-1.96	-1.93	-0.96	–	–	–	–	–	–	–	–	–	–
Sale & Maturity of Investments	–	–	–	–	–	–	-0.04	0	2.02	3.02	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	–	–	–	–	–	–	-0.04	0.00	2.00	3.02	3.14	1.93	3.05	2.11	0.13	-0.01	-15	-0.01	-0.01	-0.03	-0.02	-0.03	-0.01	0.00	0.00	0.00
Stock Issued	–	–	–	–	–	–	–	–	–	–	–	0.16	2.22	0.77	–	–	–	–	–	–	–	–	–	–	–	–
Debt Issued	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.03	0.42	0	0.28
Financing Cash Flow	1.37	0.40	17	7.03	2.47	2.40	2.31	0.81	10	-0.15	9.56	0.13	2.20	0.75	-0.02	-0.02	0.00	-0.04	-0.01	0	-0.21	42	-0.44	9.55	-0.01	1.39
Foreign Exchange Rate Adjustments	-0.14	0.02	0.10	0.01	0.26	0.11	-0.48	0.38	0.01	-0.44	0.48	-0.14	0.11	0.04	0.23	-0.11	-0.09	-0.05	0.06	0.03	0.02	-0.02	-0.01	-0.02	0.00	0.00
Net Change in Cash	-3.46	-4.30	12	2.11	-2.37	-1.31	-1.67	-4.88	6.30	-1.16	7.53	-2.05	0.33	-1.32	-3.57	-3.43	-20	-2.54	-4.10	-2.19	-3.43	39	-1.77	8.77	-0.43	0.63
Free Cash Flow	–	–	–	–	–	–	-3.46	-6.08	–	–	-5.66	-3.97	-5.03	-4.23	-3.91	-3.35	-5.10	-2.46	-4.16	-2.22	-3.24	-2.84	-1.32	-0.76	-0.42	-0.76

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -155.7%

Financial strength

Current ratio: 4.36
Debt to equity: 0.03
Debt to assets: 2.2%
Cash to current liabilities: 381.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 4.75
Dividend yield: –